Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD

Victor Aboyans (1, 2)

1 NET - Neuroépidémiologie Tropicale
2 Service de cardiologie [CHU Limoges]

Secondary prevention in patients with coronary artery disease and peripheral artery disease involves antithrombotic therapy and optimal control of cardiovascular risk factors. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) study, adding low-dose rivaroxaban on top of aspirin lowered cardiovascular events, but there is limited data about risk factor control in secondary prevention. We studied the association between risk factor status and outcomes, and the impact of risk factor status on the treatment effect of rivaroxaban, in a large contemporary population of patients with coronary artery disease or peripheral artery disease.

Mots clés: African population; Body mass index; peripheral artery disease; underweight; Secondary prevention; blood pressure; cardiovascular risk factors; cholesterol; physical activity; rivaroxaban; smoking

Domaines: Santé publique et épidémiologie

Victor Aboyans. Introducing the 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and CVD. European Heart Journal, 2019, 40 (39), pp.3217-3219. ⟨10.1093/eurheartj/ehz688⟩. ⟨hal-02448999⟩